---
title: "Kelun Pharmaceutical Gets Marketing Approval for Anti-cancer Drug"
date: "2025-02-10 13:17:50"
summary: "Sichuan Kelun Pharmaceutical received marketing approval from China's medical products administrator for its cetuximab N01 injection. The drug is indicated for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX or FOLFIRI chemotherapy regimens, according to a Feb. 8 filing with the Shenzhen bourse. Shares of the pharmaceutical..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Sichuan Kelun Pharmaceutical received marketing approval from China's medical products administrator for its cetuximab N01 injection.

The drug is indicated for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX or FOLFIRI chemotherapy regimens, according to a Feb. 8 filing with the Shenzhen bourse.

Shares of the pharmaceutical company rose 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465438:0/)
